


AMENDMENTS TO THE CLAIMS

1. (currently amended) Compound of the structural formula I:

Formula I



and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

- (a) R₁, R₂ and R₆ are each independently selected from the group consisting of hydrogen, C₁-C₈ alkyl, substituted C₁-C₈ alkyl, aryl-C₀₋₄-alkyl, substituted aryl-C₀₋₄-alkyl, C₃-C₆ cycloalkyl, substituted C₃-C₆ cycloalkyl, heteroaryl-C₀₋₄-alkyl, substituted heteroaryl-C₀₋₄-alkyl, C₃-C₆ cycloheteroalkylaryl-C₀₋₂-alkyl, substituted C₃-C₆ cycloheteroalkylaryl-C₀₋₂-alkyl, C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl and substituted C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl; wherein the substituents for said substituted alkyl, arylalkyl, cycloalkyl, heteroarylalkyl, cycloheteroalkylarylalkyl, and cycloalkylarylalkyl are from one to three substituents each independently selected from R₁';
- (b) R₁', R₃', and R₄' and R₁₉' are each independently selected from the group consisting of H, C₁-C₅ alkyl, C₁-C₅ alkoxy, C₁-C₅ haloalkyl, C₁-C₅ haloalkoxy, nitro, cyano, CHO, hydroxyl, arylC₀₋₅alkoxy, arylC₀₋₅alkyl, alkylcarboxamido and COOH;
- (c) X is an optionally substituted C₁-C₅ alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S;
- (d) Y is C, O, S, NH or a single bond; and
- (e) m is 0, 1, or 2; and

(e) R21 is selected from the group consisting of phenyl, substituted phenyl, and C₁-C₆ alkyl.

- (e) E is selected from the group consisting of hydrogen, C(R3)(R4)A, A, and (CH₂)_n-COOR19; wherein said (CH₂)_n-COOR19 is optionally substituted with a group selected from C₁-C₅ alkyl, arylC₀-C₅alkoxy, and arylC₀-C₅alkyl; and wherein

- ~~(i) n is 0, 1, 2 or 3,~~
- ~~(ii) A is selected from the group consisting of carboxyl, C₁-C₃alkylnitrile, carboxamide, sulfonamide, substituted sulfonamide, acylsulfonamide, substituted acylsulfonamide, tetrazole and substituted tetrazole;~~
- ~~(iii) R3 is selected from the group consisting of H, C₁-C₅ alkyl, and C₁-C₅ alkoxy, wherein said alkyl and alkoxy are each optionally substituted with from one to three substituents each independently selected from R3';~~
- ~~(iv) R4 is selected from the group consisting of H, halo, C₁-C₅ alkyl, C₁-C₅ alkoxy, C₃-C₆ cycloalkyl, aryl C₀-C₄ alkyl, and arylC₀-C₂alkoxy, or R3 and R4 are optionally combined to form a C₃-C₄ cycloalkyl, and wherein said alkyl, alkoxy, cycloalkyl, arylalkyl, and arylalkoxy are each optionally substituted with from one to three substituents each independently selected from R4'; and~~
- ~~(f) R19 is selected from the group consisting of hydrogen, arylmethyl, and C1-C4alkyl, wherein said arylmethyl and C1-C4alkyl, are each optionally substituted with from one to three substituents each independently selected from R19'.~~

2. (canceled).
3. (canceled).
4. (canceled).
- ² 5. (currently amended) A compound as claimed by ~~any one of~~ Claims 1, 2, 3 or 4 wherein R6 is selected from the group consisting of hydrogen, substituted C₁-C₄ alkyl, C₁-C₄ alkyl, substituted aryl-C₀₋₄-alkyl, and aryl-C₀₋₄-alkyl.
6. (canceled).
7. (canceled).
8. (canceled).
- ² 8. (currently amended) A compound as claimed by ~~any one of~~ Claims 1, 2, 3, 4, 5, 6, or 7 wherein Y is C.
10. (canceled).
- ⁴ 11. (currently amended) A compound as claimed by ~~any one of~~ Claims 1, 3, 5, 8, or ~~Claim 9, or 10~~ ³ wherein aryl is substituted phenyl.
- ⁵ 12. (currently amended) A compound as claimed by ~~any one of~~ Claims 1 through 11 ~~11~~ ⁴ wherein R2 is hydrogen and R1 is substituted phenyl.
- ⁶ 13. (original) A compound as claimed by Claim 1 or ~~12~~ ⁵ wherein substituted phenyl is substituted with a group selected from aryl, aryloxy, and arylalkyloxy.
14. (canceled).
15. (canceled).
- ⁷ 16. (currently amended) A compound as claimed by ~~any one of~~ Claims ~~1 through 15~~ ⁴ wherein the ~~E-CO₂C((CH₃)(OR21))~~-Y group is in the para position in relation to the X linker.
- ⁸ 17. (currently amended) A compound as claimed by ~~any one of~~ Claims ~~1 through 10, Claim 14, Claim 15, or Claim 16~~ ⁷ wherein R1 is selected from unsubstituted phenyl and substituted phenyl, and R6 is hydrogen.
- ⁴ 18. (currently amended) A compound as claimed by ~~any one of~~ Claims ~~1 through 17~~ ⁷ ~~16~~ wherein R1 is substituted phenyl wherein the phenyl substituent is one or two independently selected from the group consisting of CF₃, C₁-C₄ alkyl, and halo.
- ¹⁰ 19. (Currently amended) A compound as claimed by ~~any one of~~ Claims ~~1 through 18~~ ⁹ ~~Claim 18~~ wherein R1 is substituted phenyl and R2 is hydrogen.
20. (canceled).

~~11~~ ¹¹ 21. (currently amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and at least one compound as claimed by ~~any one of~~ Claims 1-20.

¹² ~~22~~ 22. (currently amended) A method of modulating a peroxisome proliferator activated receptor, comprising the step of contacting the receptor with at least one compound as claimed by ~~any one of~~ Claims 1-20.


¹³ ~~23~~ 23. (currently amended) A method of treating diabetes mellitus in a mammal, comprising the step of administering to the mammal in need thereof, a therapeutically effective amount of at least one compound of Claims 1-20.







¹⁴ ~~24~~ 24. (currently amended) A method of preventing diabetes mellitus in a mammal, comprising the step of administering to the mammal in need thereof, an effective amount of at least one compound of Claims 1-20.

¹⁵ ~~25~~ 25. (currently amended) A method of treating Syndrome X in a mammal, comprising the step of administering to the mammal in need thereof, a therapeutically effective amount of at least one compound of Claims 1-20.


26. (canceled).

¹⁶ ~~27~~ 27. A compound of Claim 1 ~~as disclosed by any one of the examples herein.~~ selected from the group consisting of:
























Chiral
















Chiral



























Docket No. X-15070

